Immunotherapy drug bolsters head and neck cancer treatment
A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk. …read more
A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk. …read more
